|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marhold M, Kramer G, Krainer M and Le
Magnen C: The prostate cancer landscape in Europe: Current
challenges, future opportunities. Cancer Lett. 526:304–310. 2022.
View Article : Google Scholar
|
|
3
|
Rebello RJ, Oing C, Knudsen KE, Loeb S,
Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG:
Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Y, Freedland SJ and Ye D: Prostate
cancer and prostatic diseases best of asia, 2019: Challenges and
opportunities. Prostate Cancer Prostatic Dis. 23:197–198. 2020.
View Article : Google Scholar
|
|
5
|
Bridges MC, Daulagala AC and Kourtidis A:
LNCcation: lncRNA localization and function. J Cell Biol.
220:e2020090452021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lang C, Yin C, Lin K, Li Y, Yang Q, Wu Z,
Du H, Ren D, Dai Y and Peng X: m(6) A modification of lncRNA PCAT6
promotes bone metastasis in prostate cancer through
IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med. 11. pp.
e4262021, View Article : Google Scholar
|
|
7
|
Wu G, Hao C, Qi X, Nie J, Zhou W, Huang J
and He Q: LncRNA SNHG17 aggravated prostate cancer progression
through regulating its homolog SNORA71B via a positive feedback
loop. Cell Death Dis. 11:3932020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghildiyal R, Sawant M, Renganathan A,
Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY and Mahajan
NP: Loss of long noncoding RNA NXTAR in prostate cancer augments
androgen receptor expression and enzalutamide resistance. Cancer
Res. 82:155–168. 2022. View Article : Google Scholar
|
|
9
|
Wang B, Xu W, Hu C, Liu K, Chen J, Guo C
and Yuan C: Critical roles of the lncRNA CASC11 in tumor
progression and cancer metastasis: The biomarker and therapeutic
target potential. Genes Dis. 9:325–333. 2022. View Article : Google Scholar :
|
|
10
|
Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y,
Zhang F, Lu Y, Zheng L, Zhang W and Li X and Li X: Long non-coding
RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin
pathway to promote growth and metastasis in colorectal cancer.
Cancer Lett. 376:62–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song H, Liu Y, Li X, Chen S, Xie R, Chen
D, Gao H, Wang G, Cai B and Yang X: Long noncoding RNA CASC11
promotes hepatocarcinogenesis and HCC progression through
EIF4A3-mediated E2F1 activation. Clin Transl Med. 10:e2202020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen
X, Nie Z and Yin J: LncRNA CASC11 promotes cancer cell
proliferation in hepatocellular carcinoma by inhibiting
miRNA-188-5p. Biosci Rep. Apr 30–2019.Epub ahead of print.
View Article : Google Scholar
|
|
13
|
Cui Y, Shen G, Zhou D and Wu F: CASC11
overexpression predicts poor prognosis and regulates cell
proliferation and apoptosis in ovarian carcinoma. Cancer Manag Res.
12:523–529. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Capik O, Sanli F, Kurt A, Ceylan O, Suer
I, Kaya M, Ittmann M and Karatas OF: CASC11 promotes aggressiveness
of prostate cancer cells through miR-145/IGF1R axis. Prostate
Cancer Prostatic Dis. 24:891–902. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Humphrey PA, Moch H, Cubilla AL, Ulbright
TM and Reuter VE: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part b: Prostate and bladder
tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q,
Zhang L, Liu C, Chen S, Wu J, et al: ciRS-7 is a prognostic
biomarker and potential gene therapy target for renal cell
carcinoma. Mol Cancer. 20:1422021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan X, Pan Q, Xin H, Chen Y and Ping Y:
Genome-editing prodrug: Targeted delivery and conditional
stabilization of CRISPR-Cas9 for precision therapy of inflammatory
disease. Sci Adv. 7:eabj06242021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mortensen MM, HØyer S, Lynnerup AS,
Ørntoft TF, SØrensen KD, Borre M and Dyrskjøt L: Expression
profiling of prostate cancer tissue delineates genes associated
with recurrence after prostatectomy. Sci Rep. 5:160182015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arredouani MS, Lu B, Bhasin M, Eljanne M,
Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA and
Sanda MG: Identification of the transcription factor single-minded
homologue 2 as a potential biomarker and immunotherapy target in
prostate cancer. Clin Cancer Res. 15:5794–5802. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang C, Xue Z, Liu Y, Xiao J, Chen J,
Zhang L, Guo J and Lin W: Delivery of anticancer drug using
pH-sensitive micelles from triblock copolymer MPEG-b-PBAE-b-PLA.
Mater Sci Eng C Mater Biol Appl. 84:254–262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada Y and Beltran H: The treatment
landscape of metastatic prostate cancer. Cancer Lett. 519:20–29.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adamaki M and Zoumpourlis V: Prostate
cancer biomarkers: From diagnosis to prognosis and precision-guided
therapeutics. Pharmacol Ther. 228:1079322021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hua JT, Chen S and He HH: Landscape of
noncoding RNA in prostate cancer. Trends Genet. 35:840–851. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021. View Article : Google Scholar
|
|
26
|
Xu YH, Deng JL, Wang G and Zhu YS: Long
non-coding RNAs in prostate cancer: Functional roles and clinical
implications. Cancer Lett. 464:37–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmad I, Fakhri S, Khan H, Jeandet P,
Aschner M and Yu ZL: Targeting cell cycle by β-carboline alkaloids
in vitro: Novel therapeutic prospects for the treatment of cancer.
Chem Biol Interact. 330:1092292020. View Article : Google Scholar
|
|
28
|
Dyshlovoy SA, Tarbeeva D, Fedoreyev S,
Busenbender T, Kaune M, Veselova M, Kalinovskiy A, Hauschild J,
Grigorchuk V, Kim N, et al: Polyphenolic compounds from lespedeza
bicolor root bark inhibit progression of human prostate cancer
cells via induction of apoptosis and cell cycle arrest.
Biomolecules. 10:4512020. View Article : Google Scholar :
|
|
29
|
Duffy MJ, Synnott NC, O'Grady S and Crown
J: Targeting p53 for the treatment of cancer. Semin Cancer Biol.
79:58–67. 2022. View Article : Google Scholar
|
|
30
|
Kim MP, Li X, Deng J, Zhang Y, Dai B,
Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, et al:
Oncogenic KRAS recruits an expansive transcriptional network
through mutant p53 to drive pancreatic cancer metastasis. Cancer
Discov. 11:2094–2111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang A, Xu M and Mo YY: Role of the
lncRNA-p53 regulatory network in cancer. J Mol Cell Biol.
6:181–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitra S, Muralidharan SV, Di Marco M,
Juvvuna PK, Kosalai ST, Reischl S, Jachimowicz D, Subhash S,
Raimondi I, Kurian L, et al: Subcellular distribution of p53 by the
p53-responsive lncRNA NBAT1 determines chemotherapeutic response in
neuroblastoma. Cancer Res. 81:1457–1471. 2021. View Article : Google Scholar
|
|
33
|
Chen Y, Hao Q, Wang S, Cao M, Huang Y,
Weng X, Wang J, Zhang Z, He X, Lu H and Zhou X: Inactivation of the
tumor suppressor p53 by long noncoding RNA RMRP. Proc Natl Acad Sci
USA. 118:e20268131182021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sanchez Y, Segura V, Marin-Bejar O, Athie
A, Marchese FP, Gonzalez J, Bujanda L, Guo S, Matheu A and Huarte
M: Genome-wide analysis of the human p53 transcriptional network
unveils a lncRNA tumour suppressor signature. Nat Commun.
5:58122014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lyabin DN, Eliseeva IA and Ovchinnikov LP:
YB-1 protein: Functions and regulation. Wiley Interdiscip Rev RNA.
5:95–110. 2014. View Article : Google Scholar
|
|
36
|
Gandhi M, Groß M, Holler JM, Coggins SA,
Patil N, Leupold JH, Munschauer M, Schenone M, Hartigan CR,
Allgayer H, et al: The lncRNA lincNMR regulates nucleotide
metabolism via a YBX1-RRM2 axis in cancer. Nat Commun. 11:32142020.
View Article : Google Scholar
|
|
37
|
Zheng X, Zhang J, Fang T, Wang X, Wang S,
Ma Z, Xu Y, Han C, Sun M, Xu L, et al: The long non-coding RNA
PIK3CD-AS2 promotes lung adenocarcinoma progression via
YBX1-mediated suppression of p53 pathway. Oncogenesis. 9:342020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Itsumi M, Shiota M, Sekino Y, Ushijima M,
Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T and Eto
M: High-throughput screen identifies 5-HT receptor as a modulator
of AR and a therapeutic target for prostate cancer. Prostate.
80:885–894. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Adams J, Casali A and Campbell K:
Sensitive high-throughput assays for tumour burden reveal the
response of a drosophila melanogaster model of colorectal cancer to
standard chemotherapies. Int J Mol Sci. 22:51012021. View Article : Google Scholar :
|
|
40
|
Yari H, Gali H and Awasthi V:
Nanoparticles for targeting of prostate cancer. Curr Pharm Des.
26:5393–5413. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mezghrani B, Ali LMA, Richeter S, Durand
JO, Hesemann P and Bettache N: Periodic mesoporous ionosilica
nanoparticles for green light photodynamic therapy and
photochemical internalization of siRNA. ACS Appl Mater Interfaces.
13:29325–29339. 2021. View Article : Google Scholar : PubMed/NCBI
|
